Important: The POPLINE website will retire on September 1, 2019. Click here to read about the transition.

Your search found 4 Results

  1. 1
    305974
    Peer Reviewed

    WHO launches taskforce to fight counterfeit drugs.

    Burns W

    Bulletin of the World Health Organization. 2006 Sep; 84(9):685-764.

    The International Medical Products Anti-Counterfeiting Taskforce (IMPACT) aims to put a stop to the deadly trade in fake drugs, which studies suggest kill thousands of people every year. "We need to help people become more aware of the growing market in counterfeit medicines and the public health risks associated with this illegal practice," said Dr Howard Zucker, Assistant Director-General for the Health Technology and Pharmaceuticals cluster of departments at WHO. The taskforce will encourage the public, distributors, pharmacists and hospital staff to inform the authorities about their suspicions regarding the authenticity of a drug or vaccine. In a parallel move, the taskforce will help governments crack down on corruption in the sections of their police forces and customs authorities charged with enforcing laws against drug counterfeiting. Drug manufacturers will be encouraged to make their products more difficult to fake. (excerpt)
    Add to my documents.
  2. 2
    803283

    Some factors influencing the regulation of pharmaceuticals in developing countries, with particular reference to Africa.

    Johnson-Romuald F

    International Digest of Health Legislation. 1980; 31(3):453-83.

    This long review discusses a few of the factors liable to influence attempts at drug regulation in developing countries, i.e., the existing situation with regard to pharmaceuticals and some of the manifold factors (psychosocial, geopolitical, etc.) that are likely to affect legislation, particularly in countries recently achieving independence, as well as all developing countries. Sections in the monograph include, an analysis of the present situation of pharmaceutical distribution and regulation in developing countries; problems in the regulation of pharmaceuticals in Africa; analysis of legislation already in force (including those countries which have communicated their legislation to WHO and those who have not and why); adequacy of pharmaceutical supplies and approriateness of legislation; priorities (e.g., pricing, regulation, importation, distribution, quality control, and substance control); and problems connected with enforcement of legal measures (e.g., unguarded frontiers, inadequacy of administration, regional uniformity of legislation, and shortage of qualified pharmacy and medical personnel). The monograph ends with published pharmaceutical legislation in developing countries, from Algeria to Zambia.
    Add to my documents.
  3. 3
    775945

    Report to donors: October 1976.

    International Planned Parenthood Federation [IPPF]

    London, England, IPPF, 1977. 428 p.

    This report describes IPPF's world-wide program from 1975-77. Financial and statistical statements are accompanied by narrative texts. In 1975 the number of family planning acceptors increased by about 5% or 1.8 million reached directly by IPPF-funded service programs. Between 1971 and 1974 the overall acceptance rate for organized family planning programs in countries with government programs was about 35/1000 women aged 15-44. The acceptance rate of IPPF-supported programs increased from 2.1 to 2.7/1000. IPPF's contribution was about 8% of the 1974 total. As a distributing and purchasing agency for contraceptive supplies and medical equipment, IPPF purchased $8.5 million worth of commodities in 1975, $7.5 million in 1976, and $7 million in 1977. About 2/3 represent oral contraceptives and condoms. The world summary of projected expenditures, 1977, includes 20.7%/information and education, 21.6%/medical and clinical, 20.4%/administration, 14.2%/commodities, 7.6%/community-based distribution, 6.2%/training, 3.2%/evaluation, and 1.6%/fund raising. Regional reports include a program description of the regional office, financial statements, clinic service statements, program descriptions of grant receiving associations, and a brief summary of expenditure.
    Add to my documents.
  4. 4
    746473

    The condom: increasing utilization in the United States.

    Redford MH; Duncan GW; Prager DJ

    San Francisco, San Francisco Press, 1974. 292 p.

    Despite its high effectiveness, lack of side effects, ease of use, and low cost, condom utilization has declined in the U.S. from 30% of contracepting couples in 1955 to 15% in 1970. The present status of the condom, actions needed to facilitate its increased availability and acceptance, and research required to improve understanding of factors affecting its use are reviewed in the proceedings of a conference on the condom sponsored by the Battelle Population Study Center in 1973. It is concluded that condom use in the U.S. is not meeting its potential. Factors affecting its underutilization include negative attitudes among the medical and family planning professions; state laws restricting sales outlets, display, and advertising; inapplicable testing standards; the National Association of Broadcasters' ban on contraceptive advertising; media's reluctance to carry condom ads; manufacturer's hesitancy to widen the range of products and use aggressive marketing techniques; and physical properties of the condom itself. Further, the condom has an image problem, tending to be associated with venereal disease and prostitution and regarded as a hassle to use and an impediment to sexual sensation. Innovative, broad-based marketing and sales through a variety of outlets have been key to effective widespread condom usage in England, Japan, and Sweden. Such campaigns could be directed toward couples who cannot or will not use other methods and teenagers whose unplanned, sporadic sexual activity lends itself to condom use. Other means of increasing U.S. condom utilization include repealing state and local laws restricting condom sales to pharmacies and limiting open display; removing the ban on contraceptive advertising and changing the attitude of the media; using educational programs to correct erroneous images; and developing support for condom distribution in family planning programs. Also possible is modifying the extreme stringency of condom standards. Thinner condoms could increase usage without significantly affecting failure rates. More research is needed on condom use-effectiveness in potential user populations and in preventing venereal disease transmission; the effects of condom shape, thickness, and lubrication on consumer acceptance; reactions to condom advertising; and the point at which an acceptable level of utilization has been achieved.
    Add to my documents.